睿知中国疾病研究地图
候选清单0

即将招募肝细胞癌未注明分期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

HAIC + Atezolizumab Plus Bevacizumab in Unresectable HCC

ClinicalTrials.gov 上登记的一项肝细胞癌开放试验,由上海交通大学医学院附属仁济医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方上海交通大学医学院附属仁济医院Renji Hospital上海医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07045558,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 6

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(6 项)收起清单
  1. 18 岁 至 75 岁;性别:不限

    登记记录的入选字段

  2. Confirmed unresectable hepatocellular carcinoma (BCLC stage B/C) by histology, cytology, or clinical diagnosis.

    入选标准第 2 条

  3. Child-Pugh class A or B7.

    入选标准第 4 条

  4. No prior systemic therapy received, with an expected survival ≥12 weeks.

    入选标准第 6 条

  5. Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 or 1.

    入选标准第 5 条

  6. At least one measurable lesion based on RECIST version 1.1.

    入选标准第 3 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:化验:血常规、肝肾功能;试验排除的其他疾病;怀孕、哺乳与避孕。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07045558,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Patients between 18 and 75 years old, with no gender restrictions.
  2. Confirmed unresectable hepatocellular carcinoma (BCLC stage B/C) by histology, cytology, or clinical diagnosis.
  3. At least one measurable lesion based on RECIST version 1.1.
  4. Child-Pugh class A or B7.
  5. Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 or 1.
  6. No prior systemic therapy received, with an expected survival ≥12 weeks.
  7. Adequate organ function meeting the following criteria:
  8. Contraception requirements: Women of childbearing age must have a negative serum or urine pregnancy test (HCG) within 7 days before enrollment and agree to use effective contraceptive methods during the trial period and for 8 weeks after the last dose. Men must either have undergone surgical sterilization or agree to use appropriate contraceptive methods during the trial period and for 8 weeks after the last dose.
  9. Willingness to voluntarily participate in the study, with good compliance and commitment to follow-up.

排除标准:Exclusion Criteria:

  1. Known intrahepatic cholangiocarcinoma, mixed hepatocellular carcinoma, sarcomatoid HCC, or fibrolamellar carcinoma.
  2. Concurrent autoimmune diseases, organ/hematopoietic stem cell transplantation history, or other malignancies.
  3. Impaired consciousness, inability to cooperate with treatment, or active psychiatric disorders.
  4. Transarterial chemoembolization (TACE), hepatic arterial infusion chemotherapy (HAIC), bevacizumab, molecular targeted therapy, atezolizumab, or other PD-1/PD-L1 inhibitors received before enrollment.
  5. Major surgery, chemotherapy, radiotherapy, or systemic therapy for lesions received within 1 month before enrollment.
  6. Use of immunosuppressants or systemic corticosteroids for immunosuppressive purposes (>10 mg/day prednisone or other equivalent drugs) within 14 days before enrollment.
  7. Severe esophageal varices or high risk of bleeding assessed by endoscopy.
  8. Evidence of decompensated liver function, including ascites, gastrointestinal bleeding, or hepatic encephalopathy.
  9. Severe organ dysfunction in major organs such as the liver, kidneys, heart, lungs, or brain.
  10. Other contraindications for interventional therapy, molecular targeted therapy, or immunotherapy.
  11. Inability to undergo scheduled follow-up or concurrent participation in other clinical trials that may interfere with this study.
  12. Other severe comorbidities deemed by the investigator to jeopardize patient safety or compromise study completion.

引自 ClinicalTrials.gov, NCT07045558, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07045558,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07045558